A meta‐analysis of randomized controlled trials evaluating sodium‐glucose co‐transporter 2 inhibitors and incidental atrial fibrillation—Is there a true benefit?

BMM has served on Advisory Board Panels for AstraZeneca and Bayer. DMC and JRP report no conflicts of interest. The peer review history for this article is available at https://www.webofscience.com/api/gateway/wos/peer-review/10.1002/dmrr.3715. The data that support the findings of this study are available from the corresponding author upon reasonable request. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.